Gilead's combination of bictegravir, emtricitabine and tenofovir alafenamide for the treatment of HIV-1 infection has been accepted for review by European regulators. A late-stage trial of the fixed-dose drug combination showed high rates of virologic suppression and no emerging treatment resistance after 48 weeks in adult patients who are treatment-naive or who are virologically suppressed and switched regimens.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.